Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

  • Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary
  • New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer
  • Phase II results for oral, targeted factor B inhibitor iptacopan (LNP023) asfirst line monotherapy in anti-C5 treatment-naïve patients with paroxysmal nocturnal hemoglobinuria
  • Updated efficacy and safety results from pivotal ELARA trial of Kymriah® (tisagenlecleucel) in relapsed or refractory follicular lymphoma
  • Data demonstrate Novartis innovation for patients and strength of its four therapeutic platforms: targeted therapies, radioligand therapy, cell and gene therapy and immunotherapy

Basel, May 19, 2021 — Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2021 European Hematology Association (EHA) Virtual Congress. More than 110 abstracts, including Novartis-sponsored and investigator-initiated trials, will be presented at the meetings.

“Our bold ambition is to extend and improve the lives of those living with cancer and serious blood disorders, and ultimately find cures,” said Susanne Schaffert, PhD, President, Novartis Oncology. “These exciting data from across our four therapeutic platforms illustrate how we are uniquely positioned to deliver transformative innovations that may bring renewed hope for patients.”

Key highlights of data accepted by ASCO:

  • Efficacy and safety results from Phase III VISION study of investigational targeted radioligand therapy 177Lu-PSMA-617
    • Phase 3 study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION) [Abstract #LBA4; oral presentation (plenary): Sunday, June 6, 1:00 PM EDT]

  • Kisqali® (ribociclib)* overall survival analysis from MONALEESA-3
    • Updated overall survival (OS) results from the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) [Abstract #1001; oral presentation: Saturday, June 5, 1:30 PM EDT]

  • Piqray® (alpelisib) long-term disease control data from SOLAR-1
    • Long-term (LT) Disease Control in Patients (pts) With Hormone Receptor-Positive (HR+), PIK3CA-Altered Advanced Breast Cancer (ABC) Treated With Alpelisib (ALP) + Fulvestrant (FUL) [Abstract #1054; poster session: Friday, June 4, 9:00 AM EDT]

  • Kymriah® (tisagenlecleucel) updated efficacy and safety results from Phase II ELARA trial in patients with relapsed or refractory follicular lymphoma
    • Efficacy and Safety of Tisagenlecleucel (Tisa-cel) in Adult Patients (Pts) With Relapsed/Refractory Follicular Lymphoma (r/r FL): Primary Analysis of the Phase 2 ELARA Trial [ASCO: Abstract #7508; oral presentation: Monday, June 7, 11:30 AM EDT] / [EHA encore: Abstract #S210; oral presentation: Friday, June 11, 9:00 AM CEST]

  • Investigational agent tislelizumab** RATIONALE 302 pivotal data in advanced/unresectable metastatic esophageal squamous cell carcinoma and Phase II data in patients with MSI-H or dMMR solid tumors
    • RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma [Abstract #4012; poster discussion: Friday, June 4, 9:00 AM EDT]
    • A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors [Abstract #2569; poster discussion: Friday, June 4, 9:00 AM EDT]

  • Early data demonstrating innovation in solid tumors with novel assets TNO155 and NIS793; further combination studies and NIS793 Phase III planned to start later this year
    • Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors [Abstract #3005; oral abstract: Friday, June 4, 11:00 AM EDT]
    • Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors [Abstract #2509; poster session: Friday, June 4, 9:00 AM EDT]

  • Analysis of pyrexia-related and efficacy outcomes with new pyrexia management algorithm in patients with stage III BRAF-mutation positive melanoma treated with adjuvant Tafinlar® (dabrafenib) and Mekinist® (trametinib)
    • Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus [Abstract #9525; poster session: Friday, June 4, 9:00 AM EDT]

  • Tabrecta® (capmatinib)*** updated analysis from Phase II GEOMETRY mono-1 trial
    • Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study [Abstract #9020; poster session: Friday, June 4, 9:00 AM EDT]

  • Lutathera® (lutetium Lu 177 dotatate)**** final overall survival data from Phase III NETTER-1 study in adults with somatostatin receptor-positive midgut neuroendocrine tumors
    • Final overall survival in the phase 3 NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumors [Abstract #4112; poster session: Friday, June 4, 9:00 AM EDT]

Key highlights of data accepted by EHA:

  • Iptacopan (LNP023) efficacy and safety results from Phase II oral monotherapy trial as first-line treatment in patients with paroxysmal nocturnal hemoglobinuria
    • First-Line Treatment of PNH Patients With Iptacopan Leads to Rapid and Durable Hemoglobin Increase by Controlling Both Intra- and Extra-Vascular Hemolysis [Abstract #S173; oral presentation: Friday, June 11, 9:00 AM CEST]

  • Subgroup analyses of REACH2 trial evaluating Jakavi® (ruxolitinib)***** in acute graft-versus-host disease
    • Efficacy and Safety of Ruxolitinib in Patients With Steroid-Refractory Acute Graft-Vs-Host Disease After Crossover in the Phase 3 REACH2 Study [Abstract #S236; oral presentation: Friday, June 11, 9:00 AM CEST]

  • Results from X2105 study of sabatolimab (MBG453), a novel immuno-myeloid therapy targeting TIM-3, in patients with a myelodysplastic syndromes and acute myeloid leukemia
    • Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients (Pts) With High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Acute Myeloid Leukemia (AML): Subgroup Analysis of a Phase 1 Study [Abstract #S168; oral presentation: Friday, June 11, 9:00 AM CEST]

  • Safety and efficacy results from the Phase II SOAR trial evaluating Promacta®/Revolade® (eltrombopag) in patients with severe acquired aplastic anemia who cannot use ATG
    • An Interventional, Phase 2, Single-Arm Study to Assess the Efficacy and Safety of Eltrombopag Combined with Cyclosporine as First-Line Therapy in Adults with Severe Acquired Aplastic Anemia (SOAR) [Abstract #S172; oral presentation: Friday, June 11, 9:00 AM CEST]

Product Information
Approved indications for products vary by country and not all indications are available in every country. The product safety and efficacy profiles have not yet been established outside the approved indications. Because of the uncertainty of clinical trials, there is no guarantee that compounds will become commercially available with additional indications.

For full prescribing information, including approved indications and important safety information about marketed products, please visit

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at

Novartis is on Twitter. Sign up to follow @Novartis at
For Novartis multimedia content, please visit
For questions about the site or required registration, please contact

# # #

* Kisqali was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals.
** In January 2021 BeiGene granted Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan through a collaboration and license agreement.
*** Tabrecta is an oral and selective MET inhibitor licensed to Novartis by Incyte Corporation in 2009. Under the Agreement, Incyte granted Novartis worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications.
**** Lutathera is a registered trademark of Advanced Accelerator Applications, a Novartis company.
***** Jakavi is a registered trademark of Novartis AG in countries outside the United States. Jakafi is a registered trademark of Incyte Corporation. Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization outside the United States.

Novartis Media Relations

Anja von Treskow
Novartis Strategy & Financial Communications
+41 61 324 2279 (direct)
+41 79 392 8697 (mobile)

Julie Masow
Novartis US External Communications
+1 862 579 8456
Fiona Phillips
Novartis Oncology Communications
+1 862 217 9396

Novartis Investor Relations
Central investor relations line: +41 61 324 7944

CentralNorth America
Samir Shah+41 61 324 7944Sloan Simpson+1 862 778 5052
Thomas Hungerbuehler        
Isabella Zinck
+41 61 324 8425
+41 61 324 7188
To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

GeoJunxion (GOJXN.AS) announces the nomination of a new CEO and CBO16.6.2021 18:00:00 CEST | Press release

Capelle aan den IJssel, The Netherlands – 16 June 2021 – GeoJunxion (GOJXN.AS) is pleased to announce today that the Supervisory Board has decided to nominate Mr. I. Vleeschouwers as its new CEO, and Mr. F. Altamura as its new CBO (Chief Business Officer). Ivo Vleeschouwers currently serving as GeoJunxion’s CFO, has been nominated as permanent CEO. He will be combining the CEO and CFO functions going forward. Mr. Vleeschouwers together with the former CEO (Mr. Jaccoud), has been an integral part in spearheading GeoJunxion’s transformation from a traditional digital map supplier, focused on one-off large deals, to a premium location content and location intelligence service provider, with a “data as a service” revenue model. In light of the recent successes of this on-going change such as the closing of location intelligence service contracts for a value exceeding Euro 600K (see press release dated 6 May 2021) and increased market interest in the new product portfolio (Eco Alert Zones a

Staten lånar 10 miljarder kronor på 50 år till 1,386 % ränta16.6.2021 18:00:00 CEST | Pressemelding

Statenlånar 10 miljarder kronor på 50 år till 1,386% ränta Riksgälden lånadei dag upp 10 miljarder kronor till en ränta på 1,386 procent i den planerade emissionen av en50-årig statsobligation. Den nya obligationen blir det längsta låneti Sveriges statsskuld. Totalt deltog ett 80-tal investerare med en budvolym på drygt 52 miljarder kronor i emissionen som genomfördes som en syndikering. Det innebär att en grupp banker sålde obligationen till villkor som Riksgälden godkänt. Obligationen prissattes till 45 räntepunkter över marknadsräntan på den tidigare längsta svenska statsobligationen som förfaller om drygt 24 år. – Jag är glad att vi har kunnat förlänga den svenska statspapperskurvan till 50 år genom denna transaktion. Med Sveriges starka statsfinanser som grund visar vi än en gång att Riksgälden kan attrahera en bred investerarbas, säger Johan Bergström, tillförordnad upplåningschef på Riksgälden. Riksgälden kommer att bygga upp den utestående volymen i den nya obligationen SGB 106

Sweden raises SEK 10 billion at 1.386 % with 50-year bond16.6.2021 18:00:00 CEST | Press release

Sweden raises SEK 10 billion at1.386%with 50-year bond The Kingdom of Sweden raised SEK 10 billion at a yield of 1.386 per cent in the planned sale of a 50-year government bond. The new bond will be the longest outstanding loan in Sweden’s central government debt. More than 80 investors participated in the syndicated sale with the total bid volume reaching above SEK 52 billion. Syndication means that a group of banks executes the transaction at terms approved by the issuer. The final pricing was fixed at 45 basis points above the yield on the Swedish government bond that was formerly the longest, maturing in just over 24 years. – I am pleased that we were able to extend the Swedish government bond curve to 50 years through this transaction. With Sweden’s strong state finances as a foundation, we have again shown that we can attract a broad investor base, says Johan Bergström, Acting Head of Funding at the Swedish National Debt Office. The Debt Office will gradually build up the outstan

Halmstads Energi och Miljö strengthens power grid for the future – with data analytics16.6.2021 14:23:17 CEST | Press release

Having a security of supply in the power grid of 99,99 percent does not make Halmstads Energi och Miljö AB (HEM) to sit back and relax. Instead, the regional Swedish energy company has declared to make digitalization of the power grid their next step forward. Installing the dInsight Analytics Platform from Dlaboratory Sweden AB (publ) has allowed the company to analyze grid data in-depth and take proactive measures to prevent outages and make grid investments. - The advantage of dLab’s system is that we can find faults in the grid, incidents, and disturbances, before they develop into major outages. This is how we want to work, proactively, before anything has happened, says Jonas Stenberg, electrical engineer at Halmstads Energi och Miljö. The collaboration between HEM and dLab started out as a pilot project in 2018 but by now dLab’s digital solution covers about 70 percent of HEM’s power grid. - It is truly inspiring to learn about HEM’s ambitions within digitalization, and their det

Skyharbour Expands its Current Drill Program at its High Grade Moore Uranium Project, Saskatchewan16.6.2021 14:00:00 CEST | Press release

VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V:SYH)(OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) is pleased to announce that it is expanding its current diamond drilling program at its flagship 35,705 hectare Moore Uranium Project, located approximately 15 kilometres east of Denison Mine's Wheeler River project and near regional infrastructure on the southeast side of the Athabasca Basin, Saskatchewan. The current drilling program at Moore is progressing well and has provided significant encouragement to expand the current 3,500 metres drilling program to a total of 5,000 metres in 12 to 14 holes. This fully funded and permitted program will focus on following-up on existing unconformity and basement-hosted targets along the high grade Maverick structural corridor as well as newly defined targets at the Grid Nineteen area. Moore Uranium Project Claims Map: Winter/S


Auction date2021-06-16LoanSeptember 2021IsinSE0014808747Coupon, %0.00Maturity2021-09-15Tendered volume, SEK mln1,000 +/- 500Offered volume, SEK mln2,400Volume bought, SEK mln1,000Number of bids5Number of accepted bids2Average yield, %-0.194 %Lowest accepted yield, %-0.197 %Highest yield, %-0.186 %Accepted at lowest yield, %70.00 Auction date2021-06-16LoanDecember 2021IsinSE0015244405Coupon, %0.00Maturity2021-12-15Tendered volume, SEK mln1,000 +/- 500Offered volume, SEK mln2,500Volume bought, SEK mln1,000Number of bids4Number of accepted bids3Average yield, %-0.193 %Lowest accepted yield, %-0.197 %Highest yield, %-0.187 %Accepted at lowest yield, %50.00 Auction date2021-06-16LoanMarch 2022IsinSE0015659529Coupon, %0.00Maturity2022-03-16Tendered volume, SEK mln500 +/- 250Offered volume, SEK mln1,100Volume bought, SEK mln500Number of bids4Number of accepted bids1Average yield, %-0.186 %Lowest accepted yield, %-0.186 %Highest yield, %-0.186 %Accepted at lowest yield, %100.00